1620 Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

1620 Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$93K	Buy	187 +12	+7%	+$5.32K	0.06%	263
2026 Q1	$78.2K	Sell	175 -3	-2%	-$1.4K	0.05%	266
2025 Q4	$80.8K	Hold	178	–	–	0.05%	253
2025 Q3	$69.8K	Sell	178 -3	-2%	-$1.25K	0.05%	265
2025 Q2	$80.6K	Sell	181 -2	-1%	-$922	0.06%	255
2025 Q1	$88.7K	Buy	183 +5	+3%	+$2.33K	0.07%	231
2024 Q4	$71.6K	Buy	178 +2	+1%	+$927	0.05%	265
2024 Q3	$81.8K	Buy	176 +7	+4%	+$3.36K	0.06%	250
2024 Q2	$79.2K	Buy	+169	New	+$73.4K	0.06%	245

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

1620 Investment Advisors's VRTX Position: Q2 2026 in Review

1620 Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 6.9% in Q2 2026, buying an estimated $5.32K and bringing the position to 187 shares worth $93K. The position accounts for 0.06% of the portfolio, ranked #263.

1620 Investment Advisors first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

1620 Investment Advisors held 187 shares of Vertex Pharmaceuticals worth $93K as of Q2 2026.
1620 Investment Advisors bought 12 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.32K.
Vertex Pharmaceuticals made up 0.06% of 1620 Investment Advisors's portfolio in Q2 2026, its #263 holding.
1620 Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.